Abstract: A method for producing an artificial bone capable of accurate molding at a joined part with appropriate strength, in which electromagnetic waves or electron beams are irradiated to a layer of at least type of powder selected from metal biomaterials, ceramics for the artificial bone and plastic resins for the artificial bone based on image data corresponding to a shape of the artificial bone, thereby effecting sintering or melting, and the thus sintered layer or melted and solidified layer is laminated, such that a surface finish step is adopted that inner faces and/or outer faces of both ends and their vicinities configuring the joined part to a human bone part are polished by a rotating tool based on the image data and also irradiation of electromagnetic waves or electron beams at both ends and their vicinities constituting the joined part is set greater than that at other regions,

Abstract: Disclosed is an artificial bone material having controlled calcium ion elution, which does not induce cytotoxicity or any inflammatory response. It is found that the elution of a calcium ion from an artificial bone material for transplantation which contains a calcium-containing substance can be prevented effectively by subjecting the carrier to a surface treatment or adding a surface-treating agent to the carrier. It is also found that the induction of cytotoxicity can be prevented and the induction of an inflammatory response can also be prevented by using the above-mentioned carrier having controlled calcium ion elution.

Abstract: An object of the invention is to provide a bone filling material capable of promoting the bone regeneration effect of a growth factor such as platelet rich plasma (PRP). Inventors of the invention anticipated that the bone filling material adsorbs a growth factor like PRP, and the combined use of the bone filling material with PRP, the bone regeneration effect of PRP might be impaired. Further, the invention is basically related to the inhibition of this adsorbing effect of the bone filling material by using a capping agent. Since the adsorbing effect of the bone filling material is thus inhibited, PRP can exert the bone regeneration effect thereof in the case of using the bone filling material together with PRP.

Abstract: A novel method for producing a bone filling material is provided. The method comprises the steps of: (a) kneading ingredient comprising calcium-based material and material comprising binder; (b) molding a predetermined shape of the mixture obtained in step (a) with an injection molding machine having a mold; (c) removing the binder contained in the mold formed in step (b) (i.e., degreasing) to obtain a degreased body; (d) and heating and sintering the degreased body obtained in step (c) to obtain a sintered body.

Abstract: It is an object of the present invention to provide a gel-forming composition which permits on-site administration and can form a gel exhibiting prescribed strength and sustained drug release, devices for the administration thereof, and a kit for medical use. A gel-forming composition which is composed of the first composition comprising a drug, a first gelling agent represented by the general formula (I) and the like, and the first diluent and the second composition comprising the second gelling agent represented by the general formula (I) and the like and the second diluent; and application devices and kits for medical use, which can hold the gel-forming composition. X1—(OCH2CH2)n—X2 (I) wherein X1 and X2 are each —R1COONHS (wherein R1 is C1-7 alkylene), —COR1COONHS, —NOCOR1—R2 (wherein R2 is maleimido), —R1NH2, —R1SH, or —CO2PhNO2, and n is an integer of 80 to 1000.

Abstract: An object of the present invention is to provide an agent for treating or preventing vasospasm. An object of the present invention is to provide an agent for treating or preventing cerebral vasospasm as well as arterial vasospasm. Further, an object of the present invention is to provide an agent for treating or preventing cerebral ischemia and cerebral infarction. The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media and to prevent or treat vasospasm and vasospasm-dependent diseases.

Abstract: A bone filling material having controlled release of a pharmaceutical agent such as a growth factor, and a drug release controlling carrier having controlled release of a pharmaceutical agent is provided by inactivating a functional group which can strongly bind to the pharmaceutical agent of the bone filling material with a blocking agent. The bone filling material and the drug release controlling carrier of the present invention comprises: a calcium-based material such as hydroxyapatite, carbonate apatite, fluorapatite, chlorapatite, ?-TCP, and ?-TCP; a blocking agent of the calcium-based material such as serine and dextran; and a pharmaceutical agent.

Abstract: The object of the invention is to provide a redifferention medium and a redifferention method for making dedifferentiated chondrocyte to be redifferentiated into original chondrocyte, the dedifferentiated chondrocyte having attenuated cartilage characteristics due to dedifferentiation during in vitro culture. Accordingly, the invention provides a redifferention medium which is used for redifferentiating the dedifferentiated chondrocyte into the original chondrocyte, and contains insulin and at least one selected from BMP-2 and analogues thereof. The invention also provides a method for redifferentiating the dedifferentiated chondrocyte into the chondrocyte by culturing the dedifferentiated chondrocyte using the redifferentiation medium. The redifferentiation medium preferably further contains T3.